Drug Importation Debate Highlights Need For Lower Rx Prices - CMS Administrator
This article was originally published in The Pink Sheet Daily
Executive Summary
The findings of the HHS importation task force and the new Medicare drug benefit will lead to lower prices for consumers, CMS Administrator McClellan tells NACDS. Fairer international pricing, including reduced prices of generics in other countries, is also a way forward, he adds.
You may also be interested in...
Rx Importation Will Have Its Day In Court: Vermont Plans Lawsuit Against FDA
Agency’s denial of Vermont’s petition to set up a “responsible” drug reimportation program leaves “no alternative” but to sue, the state says.
Global Price Control Elimination May Not Affect U.S. Rx Costs, Economist Tells ITA Panel
Payoff from elimination of price controls would be enhanced innovation, not lower costs in U.S., panelists tell Commerce Department hearing. International Rx pricing study is due Sept. 8.
HHS Importation Task Force Moves Into Writing Phase; Still Seeking Input From Health Canada
The task force is required to conclude its written report by the fall; however, HHS Secretary Thompson has asked the task force to share its findings as soon as possible. Canadian international pharmacy representative argues that Canadian law allows pharmacies to broker three-way international transactions to sell pharmaceuticals to U.S. customers.